Scientists Develop $25 Nasal Spray That Is 99% Effective Against Colds, Flu and COVID-19
Scientists at Harvard Medical School have developed a simple nasal spray, made of harmless ingredients, that can protect people against flu, colds and COVID-19 with near-100 percent success, and it costs just $25.
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
The U.S. Food and Drug Administration (FDA) has expanded its approval of Dupixent to chronic obstructive pulmonary disease (COPD).
First Nasal Self-Administered Flu Vaccine Approved by FDA
The first influenza nasal spray vaccine that can be self-administered has been approved by the U.S. Food and Drug Administration (FDA).
CDC Identifies New COVID Strain Known as XEC
A newly discovered COVID strain known as XEC continues to spread rapidly across multiple countries, including the U.S.
Lab Value Predictive of COVID-19 Disease Severity in Children
A study has found measurements of C-reactive protein (CRP), lactate dehydrogenase (LDH) and albumin are potentially predictive markers for disease severity in children hospitalized with COVID-19.
FDA Approves Filspari for Rare Kidney Disease IgA Nephropathy
The U.S. Food and Drug Administration has granted full approval to Travere Therapeutics’ Filspari (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy.
Updated COVID Vaccines Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved and granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2.
Nasal COVID-19 Vaccine Halts Transmission of SARS-CoV-2
A study by researchers at Washington University School of Medicine in St. Louis indicates next-generation vaccines that target a virus’s points of entry — the nose and mouth — may be able to contain the spread of respiratory infections and prevent transmission.
Xembify Receives Expanded Label for PI Patients
The U.S. Food and Drug Administration (FDA) has approved an expanded label for Grifols’ XEMBIFY (20% subcutaneous immune globulin [SCIG]) to include treatment-naïve patients with primary humoral immunodeficiencies (PI).
FDA Approves Additional Indication for Fibryga
Octapharma USA’s Fibryga (fibrinogen [human] lyophilized powder for reconstitution) has received U.S. Food and Drug Administration (FDA) approval for an additional indication: fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD).
